Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

Heinz Ludwig, Meral Beksac, Joan Bladé, Jamie Cavenagh, Michele Cavo, Michel Delforge, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Jean-Luc Harousseau, Urs Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen-Nativ, Larisa Mendeleeva, Hareth Nahi, Torben Plesner & 5 andre Jesús San-Miguel, Pieter Sonneveld, Miklos Udvardy, Pia Sondergeld, Antonio Palumbo

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Abstract The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.
OriginalsprogEngelsk
TidsskriftOncologist
Vol/bind16
Udgave nummer4
Sider (fra-til)388-403
ISSN1083-7159
DOI
StatusUdgivet - 2011

Fingeraftryk

Bortezomib

Citer dette

Ludwig, H., Beksac, M., Bladé, J., Cavenagh, J., Cavo, M., Delforge, M., ... Palumbo, A. (2011). Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 16(4), 388-403. https://doi.org/10.1634/theoncologist.2010-0386
Ludwig, Heinz ; Beksac, Meral ; Bladé, Joan ; Cavenagh, Jamie ; Cavo, Michele ; Delforge, Michel ; Dimopoulos, Meletios ; Drach, Johannes ; Einsele, Hermann ; Facon, Thierry ; Goldschmidt, Hartmut ; Harousseau, Jean-Luc ; Hess, Urs ; Kropff, Martin ; Leal da Costa, Fernando ; Louw, Vernon ; Magen-Nativ, Hila ; Mendeleeva, Larisa ; Nahi, Hareth ; Plesner, Torben ; San-Miguel, Jesús ; Sonneveld, Pieter ; Udvardy, Miklos ; Sondergeld, Pia ; Palumbo, Antonio. / Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. I: Oncologist. 2011 ; Bind 16, Nr. 4. s. 388-403.
@article{2593f11e96ca4e0fab9031055f0c2755,
title = "Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective",
abstract = "Abstract The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.",
author = "Heinz Ludwig and Meral Beksac and Joan Blad{\'e} and Jamie Cavenagh and Michele Cavo and Michel Delforge and Meletios Dimopoulos and Johannes Drach and Hermann Einsele and Thierry Facon and Hartmut Goldschmidt and Jean-Luc Harousseau and Urs Hess and Martin Kropff and {Leal da Costa}, Fernando and Vernon Louw and Hila Magen-Nativ and Larisa Mendeleeva and Hareth Nahi and Torben Plesner and Jes{\'u}s San-Miguel and Pieter Sonneveld and Miklos Udvardy and Pia Sondergeld and Antonio Palumbo",
year = "2011",
doi = "10.1634/theoncologist.2010-0386",
language = "English",
volume = "16",
pages = "388--403",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press, Inc.",
number = "4",

}

Ludwig, H, Beksac, M, Bladé, J, Cavenagh, J, Cavo, M, Delforge, M, Dimopoulos, M, Drach, J, Einsele, H, Facon, T, Goldschmidt, H, Harousseau, J-L, Hess, U, Kropff, M, Leal da Costa, F, Louw, V, Magen-Nativ, H, Mendeleeva, L, Nahi, H, Plesner, T, San-Miguel, J, Sonneveld, P, Udvardy, M, Sondergeld, P & Palumbo, A 2011, 'Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective', Oncologist, bind 16, nr. 4, s. 388-403. https://doi.org/10.1634/theoncologist.2010-0386

Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. / Ludwig, Heinz; Beksac, Meral; Bladé, Joan; Cavenagh, Jamie; Cavo, Michele; Delforge, Michel; Dimopoulos, Meletios; Drach, Johannes; Einsele, Hermann; Facon, Thierry; Goldschmidt, Hartmut; Harousseau, Jean-Luc; Hess, Urs; Kropff, Martin; Leal da Costa, Fernando; Louw, Vernon; Magen-Nativ, Hila; Mendeleeva, Larisa; Nahi, Hareth; Plesner, Torben; San-Miguel, Jesús; Sonneveld, Pieter; Udvardy, Miklos; Sondergeld, Pia; Palumbo, Antonio.

I: Oncologist, Bind 16, Nr. 4, 2011, s. 388-403.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

AU - Ludwig, Heinz

AU - Beksac, Meral

AU - Bladé, Joan

AU - Cavenagh, Jamie

AU - Cavo, Michele

AU - Delforge, Michel

AU - Dimopoulos, Meletios

AU - Drach, Johannes

AU - Einsele, Hermann

AU - Facon, Thierry

AU - Goldschmidt, Hartmut

AU - Harousseau, Jean-Luc

AU - Hess, Urs

AU - Kropff, Martin

AU - Leal da Costa, Fernando

AU - Louw, Vernon

AU - Magen-Nativ, Hila

AU - Mendeleeva, Larisa

AU - Nahi, Hareth

AU - Plesner, Torben

AU - San-Miguel, Jesús

AU - Sonneveld, Pieter

AU - Udvardy, Miklos

AU - Sondergeld, Pia

AU - Palumbo, Antonio

PY - 2011

Y1 - 2011

N2 - Abstract The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

AB - Abstract The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

U2 - 10.1634/theoncologist.2010-0386

DO - 10.1634/theoncologist.2010-0386

M3 - Journal article

VL - 16

SP - 388

EP - 403

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -